Medidata Launches myMedidata LIVE
Medidata, a Dassault Systèmes Company, has announced the availability of myMedidata LIVE, a new feature on the myMedidata patient portal. myMedidata LIVE is a web-based, live video conferencing capability connecting patients virtually with their clinical trial study staff.
myMedidata is Medidata’s newly released patient portal solution that provides patients with virtual access to all of their study needs in a single web application. It is built using responsive design principles, as well as input from Medidata’s Patient Insights team, made to be accessible from any device with an internet connection. Particularly relevant during the current COVID-19 pandemic when in-person visits might be restricted, myMedidata LIVE video visits between patients and sites can replace scheduled site-based appointments and allow the study team to complete its data entry in Rave while the patients remain engaged offsite through myMedidata.
“myMedidata LIVE brings a meaningful capability to the clinical research community as virtualization technologies take on an increasingly important role,” said Anthony Costello, senior vice president of mHealth at Medidata. “As part of our myMedidata patient portal, patients and sites can rely on myMedidata LIVE as an alternative way to engage when in-person site visits are challenging or impossible.”
Read the full release, here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
